Download Files:
Products Details
Product Description
– Bevasiranib sodium is a siRNA designed to silence the genes that produce vascular endothelial growth factor (VEGF). It is widely accepted that vascular endothelial growth factor (VEGF) is a key component in the pathogenesis of choroidal neo-vascularization (CNV), which is a precursor to wet age-related macular degeneration (wet AMD).
Web ID
– HY-153484A
Shipping
– Room temperature
Applications
– Cancer-Kinase/protease
Molecular Formula
– C401H463N153Na40O290P40
References
– [1]Garba AO, Mousa SA. Bevasiranib for the treatment of wet, age-related macular degeneration. Ophthalmol Eye Dis. 2010;2:75-83.|[2]Dejneka NS, Wan S, Bond OS, Kornbrust DJ, Reich SJ. Ocular biodistribution of bevasiranib following a single intravitreal injection to rabbit eyes. Mol Vis. 2008;14:997-1005.
CAS Number
– 849758-52-7
Molecular Weight
– 14224.00
SMILES
– [Bevasiranib (sodium)]
Clinical Information
– Phase 3
Research Area
– Others
Solubility
– 10 mM in H2O
Target
– Small Interfering RNA (siRNA);VEGFR
Pathway
– Epigenetics;Protein Tyrosine Kinase/RTK
Product type
– Oligonucleotides
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
